Structure-guided design of 7-azaindole FLT3 inhibitors for acute myeloid leukemia
Year: 2026
Type: article
Abstract: Background Treatment options for acute myeloid leukemia (AML) remain limited by incomplete and insufficiently durable responses to currently available therapies, highlighting the need for novel chemotypes. This study aimed to optimize a bis-7-azaindole hit and identify derivatives with FMS-like tyrosine kinase 3 (FLT3) inhibitory and antileukemic activity with favorable drug-like properties. Methods A structure-guided medicinal chemistry approach combined with structure-activity relationship (SAR) studies was employed to optimize the hit. The synthesized derivatives were evaluated for inhibition of FLT3 harboring internal tandem duplication mutations, antiproliferative activity in AML cell lines, selectivity, and lipophilic ligand efficiency. Mechanistic studies examined effects on FLT3 signaling, cell-cycle progression, and apoptosis. Biochemical kinase profiling and cellular target-engagement assays were performed for the lead compound. Selected absorption, distribution, metabolism, and excretion (ADME) properties and pharmacokinetic behavior were also investigated, and ex vivo activity was assessed in FLT3-ITD or FLT3 wild-type AML samples. Results The SAR campaign identified several key pharmacophoric requirements, including the essential role of the peripheral 7-azaindole moiety, a preference for substitution at position 2, and the importance of optimizing the basic side chain. Compound 50 emerged as the lead candidate, displaying potent inhibition of FLT3 with internal tandem duplication mutations (IC 50 = 0.163 μM), strong antiproliferative activity in FLT3-mutated AML cells (GI 50 = 0.164 μM), lipophilic ligand efficiency of 8.9, differential antiproliferative response between THP-1 and MV4-11 cells (THP-1/MV4-11 anti-proliferative ratio = 108) and biochemical kinase selectivity ratio (FLT3-WT/FLT3-ITD) of 2.0. Mechanistic studies showed reduced FLT3 and downstream signaling phosphorylation, G1-phase arrest and apoptosis. However, cellular profiling did not demonstrate clear dose-dependent FLT3 engagement and identified additional kinase targets, indicating a polypharmacological profile. Compound 50 exhibited high plasma and microsomal stability and a pharmacokinetic profile characterized by rapid distribution and persistence in bone marrow. Furthermore, it reduced leukemic blast counts in FLT3-ITD patient samples at 10 μM in stromal co-culture. Conclusions Structure-guided optimization of a bis-7-azaindole hit led to the identification of compound 50 as a FLT3-pathway-modulating chemotype with a polypharmacological profile and favorable early ADME properties. These findings support further preclinical investigation of this scaffold as a starting point for antileukemic drug discovery.
Authors: Lukas Gorecki, Darina Muthna, Jan Rataj, Denisa Sarova, Joel Rüegger, Vladimir Krystof, Radim Havelek, Miroslav Perina, Jiri Janousek, Martin Novak, Lukas Prchal, Ales Sorf, Ondrej Soukup, Jitka Odvarkova, Katarzyna Ewa Greber, Krzesimir Ciura, Jana Karasova Zdarova, Eva Pokorna, Pavel Klener, Nadezda Mazankova, Bozena Janska, Patrik Marian Sudicky, Lukas Opalka, Martin Kratky, Alzbeta Zavrelova, Benjamin Visek, Ondrej Soucek, Rajdeep Sarma, Simona Dudicova, Martina Rezacova, Martina Ceckova, Jan Korabecny
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,890
OpenAlex ID: W7225628837
FWCI:
Cites:
Cited by:
Related to: